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Abstract
Chimeric Antigen Receptor (CAR) immunotherapy utilizes genetically-engineered immune cells that express a
unique cell surface receptor that combines tumor antigen specificity with immune cell activation. In recent clinical
trials, the adoptive transfer of CAR-modified immune cells (including CAR-T and CAR-NK cells) into patients has
been remarkably successful in treating multiple refractory blood cancers. To improve safety and efficacy, and
expand potential applicability to other cancer types, CARs with different target specificities and sequence
modifications are being developed and tested by many laboratories. Despite the overall progress in CAR
immunotherapy, conventional tools to design and evaluate the efficacy and safety of CAR immunotherapies can be
inaccurate, time-consuming, costly, and labor-intensive. Furthermore, existing tools cannot always determine how
responsive individual patients will be to a particular CAR immunotherapy. Recent work in our laboratory suggests
that the quality of the immunological synapse (IS) can accurately predict CAR-modified cell efficacy (and toxicity)
that can correlate with clinical outcomes. Here we review current efforts to develop a Synapse Predicts Efficacy
(SPE) system for easy, rapid and cost-effective evaluation of CAR-modified immune cell immunotherapy. Ultimately,
we hypothesize the conceptual basis and clinical application of SPE will serve as an important parameter in
evaluating CAR immunotherapy and significantly advance precision cancer immunotherapy.
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Immunotherapy and Chimeric Antigen Receptors
(CAR)
Immunotherapy, mainly defined as harnessing a patient’s
own or third party’s immune cells to target tumors, has
become a mainstream and powerful treatment option in
cancer biology and immunotherapy [1–3]. One promin-
ent advance, engineered Chimeric Antigen Receptor T
(CAR-T) cells, was conceptually pioneered in the late
1980s by Zelig Eshhar [4], and has emerged as a front-
line therapeutic modality in immuno-oncology and im-
munotherapy [5]. Most emblematically, CD19-CAR-T
and CD19-CAR-NK, CARs with optimal co-stimulatory
signaling and clinical efficacy, have provided an impetus
for additional research in both cancer and infectious dis-
eases [6, 7], showing demonstrated beneficial outcomes
in patients with B cell lymphoma [8, 9] relapsed or re-
fractory CD19-positive non-Hodgkin's lymphoma, and
chronic lymphocytic leukemia [CLL]) [10], CAR-T cell
immunotherapy has also shown promising results for
multiple myeloma [11, 12], leukemia [9, 13–15], sarcoma
[16], and neuroblastoma [17, 18]. These findings have
led pharmaceutical companies and academic laboratories
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to extend significant investments in CAR-T or CAR-NK
cell immunotherapy [19–22]. The history of CAR-T cell de-
velopment [23], design [24–26], optimization [27], thera-
peutic resistance and challenges [2, 28], and CAR-T basic
research and clinical progress have been reviewed else-
where [29, 30] and beyond the scope of the current review.
Despite the mainstay of CAR-T biology in immune-
oncology, an array of current efforts are underway to
both improve biological efficacy and minimize side ef-
fects and toxicity [31, 32]. For example, while results of
clinical trials employing CD19-CAR-T immunotherapy
are clearly encouraging, 10-36% of these highly-selected
study patients do not respond, depending on the specific
CAR construct [33–35]. Furthermore, CAR immuno-
therapy itself is often associated with significant tox-
icity and relapse [36–40]. Given such risks, the high cost
of immunotherapy [41], and the expanding number of
CAR constructs in development, it becomes imperative
to predict which CAR constructs will be most effective
for a given cancer patient in a cost-effective and timely
manner in the era of precision medicine.
In this review, we discuss challenges inherent in
current methodologies for bringing new CAR-modified
immune cells from laboratory to clinic, focusing on
current strategies in basic research for evaluating CAR-
modified immune cell efficacy. Subsequently, we propose
novel, better time and better cost-efficient methodolo-
gies, based on the conceptual idea that the immuno-
logical synapse (IS) quality, defined as a single-cell level
of communication between an immune cell and a tumor
cell, can be a predictive biomarker for CAR efficacy and
toxicity in laboratory studies and in clinical applications
[42–46]. As such, the goal of this review is to put for-
ward the idea that (i) the quality of the CAR-T or CAR-
NK cell IS can be an accurate predictor of the antitumor
activity of CAR-modified immune cells and (ii) IS tech-
nology can form the basis of the development of fast,
easy, and inexpensive tools to predict CAR-T-cell effect-
iveness or toxicity in cancer patients. IS quality evalu-
ation also promises to establish a reliable standard for
side-by-side comparison of CAR products from different
commercial sources prior to injection into cancer pa-
tients. Below, we develop the rationale and current sta-
tus of IS evaluation in CAR-T biology. In the following
sections, we discuss current conventional methods to
predict efficacies and potential utilities of CAR-modified
immune cells, as well challenges that exist and needed
to be addressed to reduce toxicities in patients by evalu-
ating the IS quality.
Conventional Methods to Predict Efficacy of CAR
Cells
Traditionally, following design and generation of CAR-T
cells (both academic research laboratories and/or
industrial scale-ups), ranking the efficacy of CAR-
modified immune cell products has been hampered by a
number of time-consuming, costly, and labor-intensive
conventional tools used to evaluate efficacy in vivo
(Table 1).
As such, while current approaches can provide useful
information concerning the validity of the functional
CAR, these methodologies often fail to predict the effi-
cacy of CAR-modified immune cells in vivo. The lack of
a universal standard drastically complicates the evalu-
ation of product utility and functional outcomes. Clearly,
efforts to normalize CAR-T testing in a unified and con-
sensus assay, particularly in the current era of precision
medicine, would be a welcome advance to the field.
As shown in Table 1, several in vitro approaches are
currently employed to assess CAR efficacy that include;
(i) immunophenotyping, (ii) proliferation and cytokine
release, (iii) chromium release (direct cytotoxicity), (iv)
long-term killing assays and (v) interferon gamma (IFN-
γ) production. While each has some intrinsic merit with
respect to potential prediction of functional activity, all
are in vitro assays, and have to be extrapolated for
in vivo utility. Moreover, our published data as well as
those of other groups show that conventional cytokine-
based assays (e.g., IL-2 and IL-6), CD4/CD8, and Cr51
release assays do not predict CAR-T in vivo efficacy [47,
48] potentially limiting the utility of these assays to
in vivo performance. We compare the currently available
parameters in the Table 2.
The currently available strategies to evaluate the ef-
fectiveness of CAR-T cells include conventional in vitro
methods, such as immunophenotyping assay, prolifera-
tion and cytokine secretion assays, cytotoxicity assay,
and long-term killing assays, as well as in vitro strategies
for clinical use CAR-T cells (including vector copy num-
ber testing), as detailed below:
Immunophenotyping assay
The growth kinetics and immunophenotye of CAR-T
cells are typically measured for a minimum of 2-3 weeks.
Different research laboratories use different time periods
for evaluating growth kinetics, different components of
CAR-T cells (e.g., ratio of CD4 and CD8 CAR positive T
cells) and immunophenotye of CAR-T cells. This
method ensures that CAR-modified T cells retain
phenotypic and functional characteristics similar to
those of non-transduced cytotoxic T lymphocytes
(CTLs) [50].
Proliferation and cytokine secretion assay
After examining the immunophenotye and composition
of CAR-T cells, researchers typically examine whether
transduction with CAR affects T cell proliferation and
cytokine production [50–53].
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Cytotoxicity by standard 51Cr-release assay
A standard 4-hour 51Cr-release assay is the most com-
mon method to evaluate the cytotoxicity of CAR-T cells
in vitro [50]. Some laboratories also use a luciferase kill-
ing assay or other non-radiative assays (e.g., CD107a as-
says) to evaluate cytotoxicity of CAR-T cells. However,
the 51Cr-release assay is the most reliable method so far.
Long-term killing assay
Previous studies have shown that the antitumor activity
of CAR-T cells depends on long-term CAR-T cell activa-
tion, persistence, and proliferation [54]. To evaluate the
antitumor activity of CAR-T cells, a long-term, in vitro
killing assay are commonly used [50, 55]. There are also
other less common approaches, such as proteomics [56]
and sequence tools [49] as surrogates for killing efficacy.
IFN-γ production and in vitro strategies for clinical use
CAR-T cells
In the FDA briefing document “Oncologic Drugs Advis-
ory Committee Meeting for Tisagenlecleucel (Kymriah,
https://www.fda.gov/media/106081/download),” IFN-γ
production in response to tumor antigen-bearing cells,
transduction efficiency (Vector copy number [VCN] and
CAR expression), and T cell subsets are suggested. How-
ever, the results are not recommended as criteria for
CAR-T efficacy prediction.
In addition to the aforementioned in vitro cell based
assays, currently available in vivo methods for evaluating
the efficacy of CAR-modified immune cells include
xenogeneic transplantable mouse models, which mainly
employ immune-compromised NOD/SCID/gamma
chain-/- (NSG) mice that lack T cells, B cells, and NK
cells. These NSG xenograft mouse models are relatively
quick and easy, and can monitor homing, trafficking,
persistence, and anti-tumor activity of CAR-modified
immune cells in vivo in live animals using in vivo im-
aging systems [50, 57–60]. While NSG models are the
most commonly used in the field of CAR immunother-
apy, there are obvious shortcomings. Notably, NSG
mouse models cannot evaluate the effects of tumor
microenvironment (TME) and toxicity of CAR-modified
immune cells including induction of cytokine storm.
Traditionally, these in vivo NSG animal models have
mainly focused on blood cancers. For solid tumors, it is
even more challenging to evaluate the efficacy of CAR-
Table 1 Comparison of currently available methods for evaluating CAR efficacy in research lab and in clinic
Method Types Currently available Methods Assay readouts Pros Cons
In vitro assays Immunophenotyping assay ratio of CD4 and CD8 Easy and quick Cannot be used a predictive
biomarker due to variations
from each individual.




IL-2 and IFN-gamma productions Easy and quick Cannot reflect the proliferation
and cytokine productions in vivo
Cytotoxicity by standard
51Cr-release assay
4-hour killing of tumor cells Easy and quick Short -term in vitro activation
No interaction with host real
tumor cells
Long-term killing assay Number of CAR-T cells Reflects the CAR-T expansion
and tumor killing in 1- or
2-week in vitro assay
Time-consuming
Number of artificial tumor cells Artificial modified tumor cell lines
Slow and variable
Technically complex
Available in vitro Strategies
for clinical use CAR-T cells
Vector copy number (VCN)
and CAR expression
Technically convenient Cannot be used as predictive
biomarker due to variations
from each individual.
In vivo assays NSG mouse model Tumor size and tumor growth Predicts persistence of
CAR cells
No host immune system
Mouse survival Predicts CAR-T killing
capability
No tumor microenvironment (TME)




Tumor size Intact host immune system Slow and complex
Mouse survival Some TME development Model is variable
Body weight Expensive
Biodistribution of CAR cells Labor-intensive
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modified cells in clinically relevant mouse models, which
do not fully recapitulate humans [61] and such technol-
ogy cannot be used in the clinical test laboratory for
evaluating the efficacy of CAR-modified cells for each
individual patient. A summary and comparison of strat-
egies and challenges for both preclinical in vitro studies
and evaluating the efficacy of CAR-modified immune
cells in vivo is summarized in Table 1.
Collectively, while each of the aforementioned in vitro
and in vivo methods to introduce CAR modified cells
into patients have merit, the heterogeneity in methods
(including inconsistency between laboratories) and their
time-consuming, expensive, labor-intensive approaches
can be problematic for transferring CAR activity to
in vivo efficacy for each patient. Other potential prob-
lems with current in vitro CAR testing include the fact
that there are no consensus supportive tools, services, or
commercial products to evaluate CAR efficacies (most of
the assays in Table 1 and Table 2 are carried out in indi-
vidual laboratories), as well as there is considerable vari-
ability in the overall yields and scalability of the final
products. Finally, there is considerable intrinsic com-
plexity and variability of CAR-T products, such as
unique linkers, different co-stimulating molecules, differ-
ent genetically modified vectors for generating CAR-T
cells, metabolic state of CAR-T cells, and expansion
techniques. The complexity of CAR-modified cell prod-
ucts further make the reproducibility of CAR-T products
challenging. Clearly, current strategies cannot be used to
quickly screen the manufacturing process and CAR con-
structs from the CRO (Contract Research Organization)/
CMO (Contract Manufacturing Organization) industry
due to the lack of high-throughput capability, accuracy,
and reproducibility.
The above considerations are also highlighted from
the fact even in best case scenario’s that employ CAR-
Ts, such as clinical trials for Acute lymphoblastic
leukemia (ALL), Chronic lymphocytic leukemia (CLL),
Diffuse large B-cell lymphoma (DLBCL), and non-
Hodgkin lymphoma (NHL), still between 10-36% of even
these highly selected study patients do not respond to
CAR-T therapy.
CD19-CAR-modified T-cells (CAR-T) have been re-
markably successful at treating ALL [62]. With lympho-
depletion, institutional clinical trial success objective
response rates (calculated as combined complete plus
partial response rates) range from 64-82% in diffuse
large B-cell lymphoma [33] (DLBCL) and from 85-90%
in relapsed and refractory ALL on the basis of published
data in USA [13–15], depending on the CAR construct
Table 2 Summary of currently available parameters for predicting the efficacy of CAR-modified immune cells
Parameter Prediction Disease References
Pre-expansion of T cells Percentage of pre-expansion CD8 TN (naive), CD8 TCM
(central memory), TEM (effector memory), TEFF (effector)
No CLL [49]
Percentage of pre-expansion CD8 TSCM (stem cell memory) Modestly significant CLL [49]
Percentage of pre-expansion CD45RO- CD27+ CD8+ T cells Yes CLL [49]
CAR cells Infused CAR cell dose No CLL [49]
CD27+ PD-1-CD8+ CAR-T cells Yes CLL [49]
Upregulated pSTAT3 in response to IL-6 from CD27+ PD-1-
CD8+ CAR-T cells with IL-6 receptor-β chain
Yes CLL [49]
CD4/CD8 ratio No CLL [49]
CAR transduction efficiency No CLL [47, 49]
Transgene level in blood No CLL [49]
Telomere length of CAR No CLL [49]
CAR RNA-sequence Yes CLL [49]
Cytokine Serum IL-6 level Debated CLL [48, 49]
Serum IL-15 level Yes DLBCL [48]
Serum IL-10 level Yes DLBCL [48]
4-h Cr51 release No Not Applicable (NA) [47]
IFN-gamma (IFN-γ) No Not Applicable (NA) [47]
TNF-gamma No Not Applicable (NA) [47]
IL-2 No Not Applicable (NA) [47]
Others Cytokine used in culture (IL-2 vs IL-7+IL-15) No Kappa (K+) NHL [34]
Quality of immunological synapse Yes Not Applicable (NA) [47]
In Vivo Animal model Yes CLL [47, 49]
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tested. With such a high clinical response rate, no study
has been reported to predict the clinical response for
ALL treatment using CD19-CAR-T cells.
IS Quality as a Biomarker for CAR-T Cell-Mediated
Efficacy
Due to the lack of uniformly available strategies for pre-
dicting CAR efficacy in the clinic, we first proposed to
utilize a conceptually novel approach that assessed qual-
ity of the IS formed by CAR-modified immune cells in
order to predict efficacy and toxicity of CAR cells in
basic research and clinical applications [47, 63]. As such,
we posit that accurately assessing IS quality will be a
powerful utility for precisely determining the best CAR
therapy for a given patient, and that in vitro CAR-T IS
quality will serve as a proxy for CAR-T effectiveness via
a Synapse Predicts Efficacy (SPE) system for rapid (< 24
hours) evaluation of CAR-modified immune cells (in-
cluding CAR-T and CAR-NK cells, as well as other types
of CAR-modified immune cells). Importantly, this min-
imally instrumented system can be portable and oper-
able by users with minimal expertise.
As noted above, IS quality is defined as a communica-
tion between an immune cell and a tumor cells and can
be quantified by a combination of parameters that in-
clude a microscopic readouts that assess IS structure
and function, as well as signal transduction outcomes
[47, 63]. Methodologically, IS quality can be classified as
live cell IS and fixed cell IS. Live cell IS can be qualified
over a period of time. Particularly, dynamics of IS quality
can be evaluated by the glass-supported planar lipid bi-
layer system or vertical cell pairing (VCP) system to
quantify mean fluorescence intensity (MFI) of F-actin (a
cytoskeleton structural molecule required for IS
reorganization and stability), clustering of tumor antigen
(an initiator for CAR signaling), polarization of lytic
granules (LG, a maker for perforin and granzymes), and
distribution of key signaling molecules (e.g., pZeta chain,
a critical signaling molecule after CAR molecule micro-
clusters) within IS as a function of time [64]. For fixed
cell IS, primary human peripheral blood mononuclear
cells (PBMCs) can be engineered to express CAR mole-
cules against a particular tumor cell membrane antigen,
such as the GD2 disialoganglioside (GD2.CAR), which is
highly expressed in neuroblastoma (NB) [18, 65, 66].
These CAR-T cells can be stimulated by the lipid bilayer
system containing molecules (e.g., Abs or tumor anti-
gens) to trigger CAR signaling, and fixed at a particular
time point. An example of good IS quality can be simply
defined as: higher percentage of F-actin accumulation,
stronger lytic granule polarization, and stronger key sig-
naling molecule polarization within the IS, compared to
a poor IS (Fig. 1), which is illustrated by GD2-CAR by
using anti-GD2 antibody (clone, 1A7) [17],
Fig. 1 Representative CAR good and poor IS formed on the lipid bilayer. (a) Diagram of a lipid bilayer model to study GD2-CAR IS formation and
GD2-CAR-T cell activation using idiotypic antibody (clone, 1A7) against the GD2-CAR to trigger CAR signaling on the glass-supported planar lipid
bilayer system. (b) Schematic representation of three-dimensional (3D) confocal image reconstitutuin. Briefly, primary GD2-CAR-T cells were
stimulated on the SLB containing biotinylated fluorescently labeled anti-GD2-CAR (yellow), fixed, permeabilized, and then stained with phalloidin
(blue), anti-F-actin (green), and perforin (red). An individual cell was imaged under the 3D Olympus confocal setting, and then the reconstitution
of these 3D confocal images . (c & d) Comparison of good CAR IS (c) and poor CAR IS (d) is illustrated by these reconstituted 3D confocal
images. The x-y focal plane represents the lipid bilayer surface. The Z focal plane represents the CAR T cell position on the top of lipid bilayer.
Scale bars, 5μm. Notably, stronger F-actin accumulation, lytic granule polarization, and CAR molecular accumulation is associated with optimal
CAR IS
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For the lipid bilayer component, it is possible to evalu-
ate CAR-mediated immune cell IS quality in a high-
throughput, automated manner by quantitation of F-
actin, clustering of tumor antigen, polarization of lytic
granules (LGs), and distribution of key signaling mole-
cules within the IS, as well as other parameters [47]. Al-
though bilayers are artificial membranes lacking
cytoskeleton, lipid rafts, and other ligands that tumor
cells possess physiologically [67], they recapitulate im-
portant features such as the mobility and orientation of
ligands. This allows the bilayer system to serve as a “re-
ductionist approach” for dissecting the contribution of
individual receptor and ligand (e.g., CAR molecule and
its corresponding tumor antigen) in a high-throughput
manner. Combination of the lipid bilayer system with
other complementary assays (such as VCP device) can
be employed to analyze IS structure, function, and sig-
naling of CAR-T cells with actual tumor cells (either as
tumor cell lines tumor cells isolation from patients) [64].
This latter parameter allows a robust and preclinical utility
to IS quality in personalized medicine. Indeed, our prelim-
inary studies show that IS quality measured by both the
lipid bilayer system and VCP system correlates positively
with the CAR cell efficacy in two different CAR-T and
CAR-NK cells that share identical antigen specificity in
both cell based and xenograft models [47].
We anticipate that future studies that link IS quality with
other more robust quantitative outcomes (e.g., RNA-
Sequence technology) will substantiate the utility of this ap-
proach. For example, recently, RNA-sequencing (RNA-seq)
was recently used to identify (determinants of) response and
resistance to CD19-CAR-T cell therapy of chronic lympho-
cytic leukemia (CLL) [49]. Transcriptomic profiling has been
used comparing CAR-T cells from complete-responding pa-
tients with CLL versus non-responders showed enrichment
in memory-related genes, including IL-6/STAT-3 signatures,
whereas T cells from non-responders upregulated programs
involved in effector differentiation, glycolysis, exhaustion,
and apoptosis [49]. Such markers can be compared with IS
quality parameters to assess co-variance and associated out-
comes further validating IS quality as a predictive approach.
Also, IS quality can be compared with other CAR associated
variables such as vector integration sites and genetic back-
grounds of the patients. Recent studies reported that CD19-
CAR vector integration (within the host TET2 gene) was as-
sociated with CLL remission and integration-site distribu-
tions was linked to treatment outcomes [68, 69]. Potential
problems with using CAR-T RNA-seq alone and insertional
mutagenesis alone to predict efficacy includes limited focus
on the intrinsic potency of CAR-T, which in turn precludes
consideration of other factors such as the TME, the distinct
genetic background of each individual patient and the differ-
ences in tumor burden from patient to patient, encounters
with suppressive factors, and cell culture techniques.
In the following sections, we highlight scenario’s where
IS quality might be impactful in immune-oncology appli-
cations. These applications include: (i) selection of optimal
CAR products from different vendors for personalized
medicine, (ii) optimization of CAR structure and design
for preclinical studies or clinical trials, (iii) selection of re-
sponders of a universal CAR in clinical trials, and (iv) pre-
dicting initial responders to CAR immunotherapy, as well
as predicting likelihood for relapse, as detailed below.
Applications of IS Quality to Optimize CAR-
modified Immunotherapy
Selection of CARS from different vendors CAR for a
particular patient
According to the MIT NEWDIGS Research Brief (https://
newdigs.mit.edu/sites/default/files/FoCUS%20Research%2
0Brief%202018F210v027.pdf), there will be ~ 40-60 new
cell and gene therapy CAR products approved by the FDA
over the next 10 years, and while many will be designed to
target the same tumor antigen, they will be derived from
different commercial sources with intrinsically subtle and
distinct properties. Therefore, it will be become increas-
ingly important to prioritize which CAR will be most
beneficial to a given patient. A good example of such di-
chotomy are the CD19-CAR-T products, whereby Novar-
tis (Kymriah) has recently approved CAR-Ts for Acute
Lymphoblastic Leukemia (ALL), and soon to be approved
to treat Non-Hodgkin’s lymphoma (NHL), while Gilead
CD19-CAR-T cell products (Yescarta) are approved to
treat relapsed or refractory diffuse large B-cell lymphoma
(DLBCL) and NHL (after two or more than 2 lines of sys-
temic therapy), and soon to approved to treat ALL. In the
future, many additional companies are poised to join in
this space.
Indeed, due to the complexity of CAR-Ts compared to
traditional drugs (for example, the number of atoms in a
molecule of aspirin (a classic traditional medicine) is 21;
however, the number of atoms in one single CD19-
CAR-T cell is above 1014 [100 trillion]), surrogate assays
such as IS quality that address structure-activity mea-
surements will likely be required to provide information
on the best efficacy for a particular patient.
Physicians and insurance companies will also need a
novel, easy-to-use, cost-effective tool to determine which
company’s CAR product will produce the best efficacy
for a particular patient. Fig. 2 shows an example of how
the IS quality assay can be used to select the best CAR
product for a particular patient. As indicated, we have
demonstrated that CAR-T cells could form a unique,
functional IS on both lipid bilayers and in VCP system
[47, 64]. We propose to use a novel, high-throughput
microfluidics VCP system to image the IS between
CAR-T cells and target cells in a vertical orientation
[64]. This minimizes distortion artifacts of horizontal
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cell-cell conjugate imaging and provides “real life” con-
firmation of our reductionist, glass-supported planar
lipid bilayer experiments [47]. Combining the glass-
supported planar lipid bilayer system with the VCP sys-
tem will provide unprecedented characterization of IS
quality [47].
Optimizing CAR design
A second utility of IS quality in CAR screening in perso-
nized medicine will be to assess CARs with different de-
signs and structural modifications [70]. These include ,
but are not limited to (i) selection of monoclonal anti-
bodies with different affinities for the same tumor anti-
gen, (ii) selection of different size linkers, and (iii) the
use of different extracellular or intracellular domains of
co-stimulatory molecules [25]. For example, different
biotech companies use different clonotypes of CD19
antibodies in producing the CD19-CAR-T cells. These
clonotypes consist of either an identical extracellular-
domain with different intracellular domains or an identi-
cal intracellular-domain with different extracellular do-
mains, all of which can influence the functional utility of
Fig. 2 Select the best CAR from different company products for a particular patient. Blood is collected by a lab professional into a 10 ml tube
with anticoagulant as a regular specimen collection procedure in any certified blood testing laboratory. The tube can be sent directly to the
synapse testing lab without transferring to a secondary tube. PBMCs, plasma, and tumor cells can be enriched. Plasma can be used later for
mimicking tumor microenvironment by adding the patient’s plasma to the imaging system on both the lipid bilayer system and VCP system.
Meanwhile, the enriched PBMCs are placed in culture and expanded. The viral vectors containing CAR1, CAR2, CAR3, CAR4, etc. are added to
generate different versions of CAR products. These different CAR products are subjected to IS quality testing. Both the lipid bilayer chip and VCP
device can be used to evaluate IS quality. IS quality ranking reports can be presented to physicians who can use the data to prescribe the best
CAR product for a particular patient. A manufacturing company then generates this prescribed CAR with proper quality control release testing
and quality assurance review. The final product is cryopreserved and delivered to distant infusion sites, where the CAR T medicine is infused
Liu et al. Cell Communication and Signaling          (2020) 18:134 Page 7 of 20
CARs. As shown in Fig. 3, IS quality assay can rapidly rank
the predicted effectiveness of a variety of CAR constructs with
minor modifications (for example different constructs of
CD19-CAR are generated from different institutes or compan-
ies, as well as research laboratories). The rapidity and usability
of the IS quality assay not only confers significant advantages
over conventional assays but has broad potential applications
(e.g., development of CDx [companion diagnostics] device in
clinic) for researchers to quickly ascertain which constructs
have the optimized clinical value/outcome(s).
Selecting responders to a universal CAR-modified cell in
clinical trials
A third utility concerning IS quality in personalized
medicine and immunotherapy will attempt to ascertain
whether a single ‘off-the-shelf’ universal CAR product
can be effectively developed [71], and if so, which se-
lected patients it will most benefit. Clearly, while the
generation of a universal, standardized ‘off-the-shelf’
CAR-modified T cell product is conceptually meritori-
ous and would significantly reduce the cost of
Fig. 3 Optimizing CAR design for translational research. Blood is collected by a lab professional into a 10 ml tube with anticoagulant as a regular
specimen collection procedure in any certified blood testing laboratory. The tube can be sent directly to the IS testing lab without transferring to
a secondary tube. PBMCs can be enriched. The enriched PBMCs are placed in culture and expanded in vitro. The viral vectors containing CAR1,
CAR2, CAR3, etc. are added to generate different version of CAR constructs generated by a research laboratory. These different CAR constructs are
optimized to enhance the functions of CAR T. However, it is impractical to put every single construct into a preclinical study (e.g., in vivo animal
model). The CAR T cells are subjected to IS quality testing using both the lipid bilayer chip and VCP device. IS quality ranking reports can be
presented to scientists who can select the best CAR construct for a preclinical animal study, and ultimately, the optimal CAR design for
downstream clinical applications. The SPE system can identify the best CAR construct from numerous constructs by screening the IS quality
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immunotherapy, the ability to achieve global anti-tumor
ability of universal CAR-modified cells in vivo is com-
plex and multifactorial. There are multiple factors that
contributes to the clinical responses that include (i) the
intrinsic potency of CAR factors (e.g., different subsets
of CAR-T cells, etc.), (ii) tumor-specific factors (e.g., mu-
tations of tumors and inhibitory ligand expressions, etc.),
(iii) patient-to-patient variability (e.g., age, sex, disease
stages, exercise frequency, etc.), and (iv) tumor micro-
environment factors (e.g., cytokine milieu and metabol-
ism, etc.). Although the intrinsic potency of CAR factors
is, a priori, expected to be identical in the scenario of a
universal CAR cells used, aforementioned tumor factors,
patient-to-patient variability, and tumor microenviron-
ment will all impinge on efficacy. Due to these complex-
ities, while presently no single parameter can predict a
patient’s clinical outcome in the CAR-T therapy, we pre-
dict that IS quality can be utilized to select responders
to a universal CAR-modified cells (as a go/no-go to en-
roll in clinical trials), and that IS quality assays might
yield clear differences in IS structure, function, and sig-
naling between responders and non-responders (patient-
to-patient variability) by first isolating tumor cells from
patients followed by incubation in vitro with the univer-
sal CAR and assessment of IS quality (Fig. 4). As such, a
“personalized IS quality” (i.e. the quality of IS formed be-
tween universal CAR-T cells and the susceptible of a
range of tumor cells from an individual patient) could be
envisioned in conjunction with other markers used in
clinical practice as a composite clinical predictor. Such
IS quality technology can be used to allow a clinically
applicable, high-throughput test.
Predicting initial responders to CAR immunotherapy as
well as predicting likelihood of relapse
A final goal and utility of IS quality and utility will be to as-
sess dynamically whether a patient will initially respond to a
given first-in-class CAR immunotherapy, and subsequently,
if and when a patient is most prone to relapse or remain in
remission longitudinally [28, 72]. For example, to assess ini-
tial responsivity, a specific CAR-modified immune cells could
be incubated with a patient’s own tumor cells for IS quality
as outlined above. For relapse/remission longitudinal studies,
after initial CAR infusion, patient’s blood samples can be col-
lected to evaluate IS quality to determine if IS quality
changes over time in a dynamic and temporal fashion. In the
case of predicting initial responsivity, a recent clinical trial
(ClinicalTrials.gov NCT00924326) demonstrated that while
clinical remissions of lymphoma are associated with elevated
serum levels of IL-15, and to a lesser extent IL-10 [48],
serum levels of the majority of 39 other proteins (including
cytokines, chemoattractants, adhesion molecules, etc.) were
not significantly different in responders vs. non-responders
[48], which indicates other better paramentes are needed.
In another clinical trial on kappa-CAR [35] and CD30-
CAR [34] (ClinicalTrials.gov NCT00881920 and Clini-
calTrials.gov NCT01316146), outcomes studies also
show that conventional clinical measures, including per-
centage of CAR positive cells, white blood cell count,
CD4/CD8 ratios, absolute neutrophil count, and IL-6 ra-
tios do not correlate well with clinical response between
responders and non-responder. Additionally, no close
correlations between transgene levels in the peripheral
blood, pre-infusion absolute lymphocyte counts, disease
type, CAR cell dose, cytokines used in culture (IL-2 vs.
IL-7 and IL-15) and clinical response [35] are noted.
Clearly, better predictors of clinical outcome are re-
quired. IS quality evaluation may provide a tool for
determinizing patients who will or will not respond to a
particular CAR product in clinic (Fig. 4).
Finally, since CAR-T cells are considered ‘living’
drugs that differ from conventional medicines (such
as chemical compounds, nucleic acids, or proteins)
there are several caveats for CAR-T biology that must
be considered that include; (i) a subset of memory-
like CAR-modified T cells can live for decades in pa-
tients’ bodies [49]; (ii) CAR modified T cells can res-
ide in the bone marrow, when the tumor antigen has
been eradicated [9], and (iii) CAR-modified T cells
can divide and proliferate upon tumor antigen stimu-
lation. We anticipate that our current work brings
significant conceptual and technical innovation to im-
proving our understanding of CAR-T cell biology,
with the ultimate goal of providing design guidance
for CAR optimization for patients with cancer. As de-
scribed above, we propose using a novel biophysical
and high-resolution quantitative imaging approach to
evaluate CAR-T cell IS quality. This will provide an
easy-to-use predictor of efficacy against both
hematologic (e.g., leukemia and lymphomas) and solid
(e.g., neuroblastoma) tumors. For example, CAR-
modified cells can be visualized forming an IS on a
glass-supported lipid bilayer in real-time (Fig. 5) or
on a vertical cell pairing device with patient’s own
tumor cells [64]. TIRF (total internal reflection fluor-
escence) microscopy can be utilized to visually ob-
serve and measure the kinetics of IS formation and
quality, making it an extremely useful tool to predict
the efficacy of any given CAR product. As a proof-of-
concept to test this hypothesis, we chose kappa-
CD28-CAR and kappa-4-1BB-CAR constructs because
these two types of constructs we used are representa-
tive 2nd- and 3rd- generation of CAR constructs that
currently used in clinical trials by Baylor College of
Medicine (BCM) at the Center for Cell and Gene
Therapy, which allows us to collect the clinical sam-
ples in follow-up studies in the future. Given the un-
precedented pace of advances and challenges in
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Fig. 4 (See legend on next page.)
Liu et al. Cell Communication and Signaling          (2020) 18:134 Page 10 of 20
immunotherapy for cancer, it is imperative that we
are able to rapidly and uniformly rank the efficacy of
various CARs with different optimizations from differ-
ent investigators and pharmaceutical companies. Our
assay for IS quality assessment is expected to fulfill
many of these urgent needs.
Current Challenges in CAR-modified Immune Cell
Therapy
Significant Toxicity of CAR-T Cell Immunotherapy
The above discussions have focused on a conceptual idea
that IS quality can better predict CAR efficacies in engi-
neered CAR cells. Ultimately, we also posit that IS qual-
ity may also have predictive value in assessing and
predicting toxicities and side effects commonly observed
with CAR-T biology in vivo. Clearly, a standardized pre-
clinical assay(s) that might predict subsequent toxicities
could potentially reduce life-threatening toxicities [36–
40] and deaths [39, 73, 74]. Common target effects of in-
clude, tumor lysis syndrome, gastrointestinal bleeding
and perforation, myelosuppression-related infections,
cytokine release syndrome (CRS), anaphylaxis, graft ver-
sus host disease (GvHD), allergy, and autoimmunity
caused by T cell products [36, 75] and CAR-related
neurologic events [15, 36]. However, generally, common
toxic side effects of CAR-modified immune cells can be
broadly divided into the following categories: CRS,
neurotoxicity, on-target and off-tumor effects of CAR-T
cells, cardiotoxicity, and hypersensitivity reactions to
CAR-modified cells [15, 36, 76]. Predicting co-variance
in the side effects and toxicities with IS quality may have
therapeutic potential in cancer immune-oncology.
Below, we summarize major toxicities of CAR and po-
tential mechanisms.
Cytokine release syndrome (CRS)
The most common toxicity of CAR-modified immune
cells is CRS, although exact molecular mechanisms of
CRS are not fully understood. CRS is defined as an exces-
sive cytokine release (IL-1, IL-6, IFN-γ, and IL-10) by
CAR-modified immune cells or bystander innate immune
cells (e.g., macrophages, monocytes, dendritic cells, and
other immune cells). These excess cytokines (driven
mainly by IL-6) can cause vascular leakage with associated
respiratory failure, coagulopathy, and multi-organ system
dysfunction [77]. One potential mechanism for CRS is that
CAR-T activated cells produce a large amount of inter-
feron gamma (IFN-γ) and/or tumor necrosis factor alpha
(See figure on previous page.)
Fig. 4 Select patients who will respond to treatment with universal CAR-modified cells or a particular CAR product. To select responders for a
particular CAR treatment, tumor cells or plasma can be isolated from 8 ml of peripheral blood from each patient. CAR cell IS quality can be assessed by
lipid bilayer and VCP device. Briefly, blood is collected into a 10 ml tube with anticoagulant as a regular specimen collection procedure. The tube can
be sent directly to the synapse testing lab without transferring to a secondary tube. PBMCs, plasma, and tumor cells can be enriched. Plasma can be
used later for mimicking the tumor microenvironment by adding the patient’s plasma to the imaging system on both the lipid bilayer system and VCP
system. Meanwhile, the enriched PBMCs are placed in culture and expanded. The viral vector containing the universal CAR construct such as CD19-
CAR, is added to generate CAR products. These universal CAR products are subjected to IS quality testing. Both the lipid bilayer chip and VCP device
can be used to evaluate the IS quality of universal CAR products in response to tumor cells isolated from each individual patient. IS quality ranking
reports can be presented to physicians who will base their decision of which CAR product to prescribe. The informed physicians can select a particular
patient (responder) for a particular CAR treatment or clinical trial. Meanwhile, for non-responders, IS testing can identify another suitable CAR therapy.
The manufacturing company generates the prescribed CAR for this patient with proper quality control release testing and quality assurance review.
The final product is cryopreserved and delivered to infusion sites, where the CAR T medicine is infused
Fig. 5 Kinetics of IS formation in live Kappa-CAR T cells under total
internal reflection fluorescence microscopy (TIRF) to evaluate the
dynamics of CAR IS quality. All cells were imaged by TIRF microscopy on
lipid bilayers carrying Kappa protein conjugated with Alexa Fluor 488 at
the indicated time points. a Kappa-41BB cells were imaged at 1 min, 3
min, 5 min, 10 min, 20 min, and 30 min. Time-lapsed differential
interference contrast (DIC) (top panel) and TIRF (bottom panel) images are
shown. b Kappa-CD28 cells were imaged at 1min, 3min, 5min, 10min,
20min, and 30min. Time-lapsed DIC (top panel) and TIRF (bottom panel)
images are shown. c Schematic representation of recombinant retroviral
vectors encoding kappa-CAR. Both Kappa-CD28-CAR and Kappa-4-1BB-
CAR constructs (CD28 and 4-1BB) contain CD28 transmembrane domain
and intracellular domain of CD3 zeta. The difference between Kappa-
CD28-CAR and Kappa-4-1BB-CAR constructs is that Kappa-4-1BB-CAR
construct contains intracellular domain of 4-1BB molecule
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(TNF-α) that subsequently activates macrophages, den-
dritic cells, and endothelial cells. These cells activated by
IFN-γ or TNF-α can further release proinflammatory cy-
tokines (e.g., IL-6). Excess IL-6 produced by activated
macrophages and endothelial cells provide positive feed-
back to further activate CAR-T cells and other immune
cells, leading to CRS [78, 79]. In addition to IL-6 [15, 80],
recent studies show that IL-1 also plays an important role
in CRS [81, 82], whereby an IL-1 receptor antagonist,
(Anakinra) can effectively control CRS and neurotoxicity
in humanized mice [81]. This finding requires further test-
ing in clinical trials. Additionally, recent studies have
shown that myeloid-derived catecholamines are essential
mediator for CRS in MTR (metyrosine) and ANP (atrial
natriuretic peptide) mouse model [83]. Importantly, the
FDA-approved catecholamine synthesis blocker metyro-
sine (Demser) can reduce the CRS without impairing the
CD19-CAR-T cell therapeutic response. Compared to
tocolizumab (a humanized monoclonal antibody against
the interleukin-6 receptor), Demser is much inexpensive
to manufacture, however, the effects of Demser require
further testing in clinical trials.
Neurotoxicty
Neurotoxicity is also a potentially life-threatening toxicity
in patients treated with CAR-T cell therapy, but etiologic-
ally, also not completely understood. Symptoms broadly
include hallucinations, encephalopathy, seizures, aphasia,
headaches and most seriously, rapidly progressive cerebral
edema [84]. The incidence of neurotoxicity is variable in
patients (0 - 50%) [13–15, 85–89], that in part depends on
the different types of CAR constructs used, and can occur
in either the presence or absence of CRS. A number of
studies have shown trafficking of CAR cells in the central
nervous system (CNS) or cerebrospinal fluid of patients
who experience neurotoxicity, but not in brain areas [13,
14, 90] where it is thought that cytokine-mediated inflam-
mation also contributes to neurotoxicity [91].
In addition to the direct attack of CAR-T cells on the
CNS, patients with severe neurotoxicity showed evidence
of endothelial activation, including disseminated intra-
vascular coagulation, capillary leak and increased blood–
brain barrier (BBB) permeability [39]. In the brains of
mice experiencing CRS, damage to the intestinal-
epithelial barrier and subsequent infiltration of T cells
was detected, suggesting yet another potential mechan-
ism of neurotoxicity [84, 92, 93].
Cardiotoxicty
Clinically, cardiovascular manifestations of CRS include
hypotension, troponinemia, arrhythmias (including
tachycardia), decreased left ventricular systolic ejection
fraction, and QT prolongation [13–15]. The reduction in
cardiac output associated with CRS is similar to that of
stress-induced cardiomyopathy seen in sepsis, but spe-
cific pathophysiologies remain unclear [94, 95]. Cardiac
arrest can occur seven days after CAR-T cell infusion in
patients with acute lymphoblastic leukemia (ALL). There
have also been reports of a left ventricular ejection frac-
tion that was 25% of the normal baseline [8, 87, 96–98].
On-target/off-tumor toxicties
“On-target/off-tumor” toxicity, in the form of chronic B
cell aplasia, is considered a tolerable side effect of this
therapy as it can be treated with intravenous immuno-
globulin (IVIG) replacement therapy [99, 100]. Addition-
ally, hypersensitivity reactions (anaphylaxis or allergy) to
CAR-modified cells can be related to host recognition of
infused foreign antigen because the majority of CAR-T
cells contain mouse monoclonal antibody (mAb). When
multiple infusions of CAR-T cells are applied, the allergy
reaction occurs. Using humanized antibody in CAR de-
sign is important in reducing hypersensitive reactions to
CAR-T cells [36].
Finally, in addition to significant toxicities and comor-
bidities by infused CARs, there is significant tumor re-
lapse after CAR-mediated immunotherapy [101, 102].
Multiple clinical trials (e.g., ClinicalTrials.gov numbers,
NCT01626495, NCT01029366 and NCT02208362) have
demonstrated that the cause or potential cause of tumor
relapse in CAR-T cell immunotherapy targeting CD19
and IL-13Rα in patients with ALL and glioblastoma is
the loss of antigen [13, 103]. Among these world’s lead-
ing academic institutions on cell and gene therapy, in-
cluding Memorial Sloan Kettering Cancer Center
(ClinicalTrials.gov number NCT01044069) on B Cell
ALL [15, 77, 104], Baylor College of Medicine (Clinical-
Trials.gov number NCT00840853) [105], National Can-
cer Institute (ClinicalTrials.gov number NCT01593696)
[14], Fred Hutchinson Cancer Research Center (Clinical-
Trials.gov numbers NCT02028455 and NCT01865617),
several clinical trials show different cases of relapse in
these complete remission patients [85]. According to
these and other reports from other countries, tumor re-
lapse after CAR-mediated immunotherapy is significant.
In addition to tumor antigen loss and mutations [106,
107], the precise mechanisms for relapse after CAR ther-
apy remain elusive [108].
Collectively, there is a great unmet need to predict and
reduce potentail toxicities from CAR products. We posit
that features of the IS quality synapse can be useful to
predict certain toxicties of CAR products mentioned
above. Further studies that compare responders with IS
quality are required to substantiate this research field.
Challenges of CAR immunotherapy in solid tumors
A further consideration will be to utilize IS quality to
predict the success of novel tumor associated antigens
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identified on solid cancer cells. As noted above, while
CAR-T immunotherapy has been remarkably successful
in treating hematological malignancies, CARs have lim-
ited effects in solid tumors and face many challenges in
solid tumor CAR-T clinical trials [109]. Identifying a
unique tumor-associated antigen (TAA) in most cancers
remains the primary challenge to employing CAR-T im-
munotherapy for treatment of solid tumors. Ideally,
tumor-restricted antigens should mainly be expressed on
the tumor cell surface and exclusively expressed in tu-
mors but not in healthy tissues to avoid potential im-
mune reactions against healthy tissues due to “on-target/
off-tumor” toxicity [70, 110–115]. Nearly 30 types of cell
surface antigens that are highly expressed by solid tu-
mors are currently being investigated as targets for
CAR-T cell therapy [113, 116]. However, none of them
are expressed exclusively on tumor (including both li-
quid and solid tumors) cell plasma membranes.
The local tumor microenvironment (TME) poses an-
other important challenge to CAR-T cell immunother-
apy in solid tumors [117], as well as the IS quality.
Various physical and environmental barriers (e.g., extra-
cellular matrix) that surround solid tumors are not
present in liquid cancers. Thus, CAR-T cells have diffi-
culty in locating to and accessing the solid tumors and
insufficient penetrance of CAR-T cells into solid tumor
tissue remains a major impediment to this research field
[118]. Additionally, chemokines uniquely secreted in the
TME of solid tumors, such as CXCL12, can engage
CXCR4 on the CAR-T cell surface and inhibit T-cell mi-
gration into the tumor [119, 120]. Endothelin B receptor
(ETBR) on the endothelium of blood vessels within the
tumor reduces T-cell adhesion and compromises their
ability to extravasate [121]. The TME also impairs the
trafficking and infiltration of CAR-T cells into solid tu-
mors through other potential mechanisms, such as the
CCR2/CCL2 axis, regulatory subunit I anchoring dis-
rupter (RIAD) peptide, extracellular matrix proteins, oxi-
dative stress, nutrient starvation, low pH and hypoxia
[114, 122–125]. In addition to these ‘chemical exclusio-
n’of CAR-T cells from tumor beds by these chemokines
and receptor/ligand interactions, the ‘physical exclusion/
barriers’ of CAR-T cells from tumor beds by collagen
fiber bundles or extracellular matrix deposition may add
another layer of complex of CAR-T cell trafficking and
infiltration into solid tumors [26, 126].
Additioanlly, immune checkpoint molecules can also
affect CAR-T immunotherapy [127–129]. While block-
ades via the programmed cell death protein-1 (PD-1) re-
ceptor and cytotoxic T-lymphocyte antigen 4 (CTLA-4)
have led to breakthroughs in cancer immunotherapy
[130], interestingly, CAR-T cells also express PD-1 and
CTLA-4, and others [131]. For examples, recent studies
show that exhausted CAR-T cells express other
inhibitory immune checkpoint receptors, such as T-cell
immunoglobulin and mucin-domain containing-3 (TIM-
3) [130]. The immune inhibition induced by PD-1 and
other inhibitory receptors can be exploited by a variety
of tumor and stromal cells expressing the programmed
cell death ligands (e.g., PD-L1 and PD-L2) or CTLA-4
[132–134]. Recent studies show that modifying CAR-T
cell to secrete PD-1-blocking single-chain variable frag-
ments (scFv) [135] or replace PD-1 inhibitory signaling
domain with CD28 activating domain [136] can enhance
the efficacy of CAR-T cells by modulating the TME.
However, other studies also show PD-1 knockdown im-
pairs in vivo persistence and proliferation of CAR-T cells
[137]. Presently, the optimal way to modulate PD-1 sig-
naling in CAR-T remains incompletely understood.
The anti-inflammatory and pro-inflammatory cytokine
environment also play an important role in regulating
CAR-T functions [138, 139]. These factors may also
affect the IS quality. Suppressive immune cells in the
TME often preferably express pro-tumor Th2 secreted
cytokines, such as IL-4 and IL-13, rather than anti-
tumor Th1 (e.g., IL-2 production), or secreted cytokines
like IFN-γ and tumor necrosis factor-β (TNF-β) [140,
141]. Cytotoxic T-cell functions are inhibited by cyto-
kines such as IL-4, IL-10 and transforming growth factor
(TGF)-β, which are secreted by suppressive immune
cells in the TME such as regulatory T (Treg) cells,
myeloid-derived suppressor cells, and tumor-associated
macrophages/neutrophils. These cells are generally
thought to represent a significant barrier against CAR-T
cell functions [142].
Metabolism-associated immune suppression in the
TME also inhibits CAR-T cell functions [143]. Cancer
cells are highly metabolically active and have relatively
high amounts of glycolysis and glutaminolysis [144].
These metabolic pathways result in a distinct accumula-
tion in the TME of metabolites such as lactate, prosta-
glandins, cyclooxygenase (COX)-1/2, indoleamine-2,3-
dioxygenase (IDO), tryptophan-2,3-dioxygenase (TDO),
arginase-1 and nitric oxide synthase (NOS) [145]. The
exact molecular mechanisms by which these factors may
compromise CAR-T functions are the subject of emer-
ging research in the field of immunotherapy.
The High Cost of CAR Therapy
A final consideration is whether is whether IS quality
can be used to ultimately reduce costs of CARs. The cost
of CAR-based immunotherapy is currently prohibitive
[41]. The “list price” for a single infusion of tisagenle-
cleucel (Kymriah) from Novartis (Basel, Switzerland) is
$475,000. The price for axicabtagene ciloleucel (Yes-
carta) from Kite Pharma (a Gilead Company, Los
Angeles, CA) is $373,000 [146]. One estimate has the
cost as high as $1.2 million per injection. Together, with
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the variety of CAR constructs already available and those
in development, it is becoming imperative to predict
which construct is likely to work best for an individual
patient prior to embarking on treatment, which is also
crucial to clinical trials. The field has been divided into
two pathways to reduce the high cost of CAR therapy.
The first pathway is to generate the universal, ‘off-the-
shelf’ CAR [147], which includes CAR-T cells with
MHC, TCR deletion, or antigen-targeting domain split
[148]. The second pathway has been focused on NK cells
[63, 149, 150], NKT [151], and γδT cells [71]. Clearly,
due to the high cost of CAR therapy, it is imperative to
develop surrogate tools to predict the efficacy and tox-
icity of CAR products.
Perspectives
The therapeutic value of CAR-mediated immunotherapy
for hematologic malignancies and promised therapeutic
value in more and more cancers, including solid tumors,
has led to explosive growth and development of CAR-
based immunotherapy. As developed in this review, the
potential for IS quality to serve as a proxy for CAR-
modified immune cell effectiveness with the ultimate
goal of inducing complete remission in patients with an
expanding number of cancers represents an exciting new
dimension in CAR biology. The SPE system under devel-
opment promises to address many challenges to the ap-
plicability of new CAR-T constructs and adoptive CAR-
T cell transfer into individual patients. However, to de-
velop SPE, additional challenges in both basic and clin-
ical research still remain: In characterizing the basic
biology of IS’s, we do not yet know:
1) Kinetics: A. What is the difference in
immunological synapse dynamics between CAR and
T cell receptors (TCR)? B. What is the activation
threshold for CAR cells on the level of a single IS?
How many molecules of CAR per IS are sufficient
to fully activate a CAR-T or CAR-NK cell? How
does the IS quality contribute to signal strength? Is
the IS quality a cause or an effect of CAR signaling
strength? C. What is the best way to quantify the
dynamic IS quality over time?
2) Immune cell biology: A. What is the influence of
various in vitro culture medium or individual
plasma environments (e.g., anti-/pro-inflammatory
cytokines) on culturing human CAR-T cell IS? B.
What is the best way to engineer and manufacture
Fig. 6 Potential Multiple Factors Determine the Quality of Immunological Synapse in Cancer immunotherapy. The development of a novel SPE
approach to predict the effectiveness of Chimeric Antigen Receptor (CAR)-modified cells by quantifying the quality of immunological synapse is
dependent on multiple factors. In addition to patient conditions (e.g., age, sex, tumor burden, stage of diseases, tumor antigen mutations & loss,
etc.), there are three main aspects to be considered to quantify the quality IS. First, intrinsic potency of CAR-modified immune cells includes
different subsets of CAR-modified immune cells, different modifications of CAR constructs, inhibitory receptor expression, and CAR tonic signaling.
Second, intra-tumor heterogeneity (IHT) includes mutations of tumors, inhibitory ligand (e.g., PD-L1) expression, suppressor cells, and tumor
stiffness. Third, tumor microenvironment (TME) contains cytokine milieu, metabolites, hypoxia, and collagen fibers around tumor cells
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optimum T cells without inducing exhaustion of
CAR-T cell IS? One potential issue regarding CAR-
T expansion in vitro using antibodies (e.g., anti-CD3
and anti-CD28) in the presence of cytokine (e.g.,
IL-2) is that the CAR-modified cells become
exhausted after rapid proliferation and differenti-
ation [152]. For example, CAR-modified immune
cells express exhaustion markers such as PD-1
[153–156]. Does PD-1/PD-L1 engagement (or other
inhibitory receptor signaling) change the IS quality?
Does co-stimulatory molecule engagement (e.g.,
CD28/CD80, OX40/OX40L, etc.) change the IS
quality? C. How can immunosuppressive check-
points on the surface of CAR cells be managed?
How do CAR cells develop into memory-like CAR
cells on the level of IS? What is the difference be-
tween memory-like CAR-T IS and naïve CAR-T IS?
3) Translational research: A. What is the distribution
and localization of CAR cell IS in peripheral organs
after infusion? B. How do CAR cells pass the blood-
brain barrier on the level of IS? C. What are the ef-
fects of exosomes released by tumor cells on the
quality of IS formed by CAR cells? D. Which mol-
ecule within CAR IS can be used as the most effect-
ive marker for judging the IS quality? E. Does intra-
tumor heterogeneity (ITH) affect the CAR-T IS
quality? TMC, intrinsic potency of CAR-T, and
ITH are three main factors that may determine
CAR-T IS quality (Fig. 6). What is the hierarchy
among these three factors?
Fig. 7 The various branches of evaluating cancer immunotherapy metaphorically represented as a Rubik’s cube. The development of a novel
approach to predict the effectiveness of Chimeric Antigen Receptor (CAR)-modified cells by quantifying the quality of CAR IS will introduce a new
parameter to the rapidly expanding field of cancer immunotherapy. Currently, no single parameter can predict the clinical outcome or efficacy of
a specific type of CAR-modified cell. IS quality will serve as a quantifiable measure to evaluate CAR products and can be used in conjunction with
other conventional parameters to form a composite clinical predictor. Much like a Rubik’s cube has countless configurations, several methods and
combinations of clinical metrics have arisen for evaluating the ability of a given immunotherapeutic strategy to treat cancer. The quality of IS
depicting cancer immunotherapy is metaphorically expressed as a Rubik’s cube. Each face/color represents one aspect of cancer therapy. Each
grid in one face indicates one factor within that aspect of cancer therapy. For example, the green color represents the tumor microenvironment,
and one out of the nine grids in the green color indicates suppressor cells (suppressors in green). Changes in one factor may completely alter the
entire strategy of cancer therapy. However, the quality of IS (illuminated center red grid) makes the effectiveness of CAR
immunotherapy predictable
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The pressing clinical questions addressed in this re-
view attempt to investigate the feasibility of using CAR-
T cell IS quality as a marker for CAR-T effectiveness in
individual patients. The proposed concept of SPE im-
pacts public health and addresses a key immunobiologi-
cal knowledge gap to define the dynamics of the CAR-T
cell IS and understand the underlying molecular basis of
CAR IS. The potential application of SPE can be classi-
fied into two main aspects: basic research application
and clinical research application. Development of high-
throughput functional screens to identify high-
performance CAR-modified immune cells and continu-
ing immunobiology of CAR research are both required
to optimize CAR cell biology. Clinical research applica-
tions include development of high-throughput screens
to identify responder and non-responder patient popula-
tions and development of high-throughput screens to se-
lect the best CAR for a particular patient.
Conclusions
Time is of the essence for development of this test to
predict the efficacy and toxicity of CAR cells. Accurate
predictors of efficacy and toxicity are required to reduce
costs as well as minimize the time it takes to get the ap-
propriate therapy to patients. While many groups are
experimenting with a variety of CAR constructs, we be-
lieve IS quality is the first to investigate a uniform, con-
crete and patient-specific way to rank their efficacy.
According to the Precision Medicine Initiative (https://
ghr.nlm.nih.gov/primer/precisionmedicine/definition),
precision medicine is “an emerging approach for disease
treatment and prevention that takes into account indi-
vidual variability in genes, environment, and lifestyle for
each person.” As the “Rubik’s Cube” for evaluating can-
cer immunotherapy (Fig. 7) becomes more and more
complex, developing a universal parameter to deliver the
highest quality therapy to patients is critical. However,
this SPE concept needs to be tested carefully because the
attributing factors of clinical response include more than
hundreds of parameters. The IS quality cannot serve as a
‘one size fits all’ role in determining the efficacy of CAR
therapy. However, the concept of SPE can be used as a
key parameter in conjunction with other conventional
parameters to form a composite clinical predictor in the
future.
Hopefully, the proposed SPE approach will tailor CAR-
T cell immunotherapy to individual patients with specific
cancers – saving time, money and ultimately, lives.
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